SELLAS Life Sciences Group, Inc

(NASDAQ:SLS)

Latest On SELLAS Life Sciences Group, Inc (SLS):

Date/Time Type Description Signal Details
2023-05-12 00:38 ESTNewsSELLAS Life Sciences GAAP EPS of -$0.47 misses by $0.18N/A
2023-03-16 23:15 ESTNewsSELLAS Life Sciences GAAP EPS of -$2.13 misses by $0.03, revenue of $1M in-lineN/A
2023-02-24 22:17 ESTNewsSellas Life Sciences dips after pricing $20M securities offeringN/A
2023-02-23 19:33 ESTNewsSELLAS stock slides -32% after launching stock and warrants offeringN/A
2022-11-14 15:03 ESTNewsSELLAS Life Sciences GAAP EPS of -$0.34 beats by $0.05N/A
2022-11-14 15:03 ESTNewsSELLAS falls 39% after delaying key milestone for cancer drugN/A
2022-11-10 23:10 ESTNewsSellas rises as GPS/Keytruda combo shows survival, disease control benefit in ovarian cancer trialN/A
2022-08-12 07:49 ESTNewsSELLAS Life Sciences GAAP EPS of -$0.41 misses by $0.02N/A
2022-08-10 05:35 ESTNewsSELLAS Life Sciences rises 9% after cancer drug shows promising result in animal studyN/A
2022-06-27 15:37 ESTNewsSellas posts positive data from phase 1 trial of lymphoma, acute myeloid leukemia therapyN/A
2022-06-17 01:19 ESTNewsSELLAS Life Sciences Group (SLS) Investor Presentation - SlideshowN/A
2022-06-09 00:39 ESTNewsSellas' GPS, Opdivo combo shows promise in early stage study in type of lung cancerN/A
2022-05-26 17:45 ESTNewsSellas announces topline data for lead asset in Ovarian cancerN/A
2022-05-13 00:44 ESTNewsSELLAS Life Sciences GAAP EPS of -$1.05, revenue of $1MN/A
2022-04-06 21:12 ESTNewsSellas Life Sciences gets China regulator nod to start trial of immunotherapy 3D189N/A
2022-04-01 12:06 ESTNewsSELLAS Life Sciences plunged 24% on $25M stock offeringN/A
2022-03-31 17:59 ESTNewsSellas Life Sciences stock slumps on securities offeringN/A
2022-03-31 17:59 ESTNewsSellas Life Sciences licenses CDK9 inhibitor from China's GenFleet TherapeuticsN/A
2022-02-02 08:19 ESTNewsSellas, Merck complete enrollment in GPS-Keytruda combo phase 1/2 trial in ovarian cancerN/A
2022-01-27 20:28 ESTNewsSELLAS Life Sciences' IND application for galinpepimut-S accepted in ChinaN/A
2021-11-24 05:30 ESTNewsSellas Life announces final court approval of settlement of derivative litigationN/A
2021-11-24 05:30 ESTNewsWarning: SLS is at high risk of performing badlyN/A
2021-11-13 03:57 ESTNewsSELLAS Life Sciences EPS misses by $0.09N/A
2021-08-13 00:18 ESTNewsSELLAS Life Sciences EPS beats by $0.11N/A
2021-07-22 01:01 ESTNewsSellas Life Sciences nabs new U.S. patent for galinpepimut-s combo in WT1-expressing cancersN/A
2021-07-22 00:57 ESTNewsSELLAS Life Sciences updates on at-the-market offeringN/A
2021-07-22 00:31 ESTNewsSELLAS Life Sciences shares rise on data from early-stage galinpepimut-S studyN/A
2021-07-22 00:23 ESTNewsSELLAS ovarian cancer candidate shows promise in early-stage trialN/A
2021-07-21 23:56 ESTNewsSELLAS rated new overweight at Cantor noting the potential of blood cancer therapyN/A
2021-03-24 06:05 ESTNewsSELLAS Life Sciences EPS misses by $0.28N/A
2021-02-23 02:51 ESTNewsSellas: Late-Stage Biotech Approaches 2023 Approval With Solid FundingN/A
2021-02-04 01:42 ESTNewsSELLAS Life Sciences jumps 43% after Reddit mentionsN/A
2020-12-23 04:40 ESTAnalyst RatingThe Analyst Target Price has increased from $8 to $10.Buy
2020-12-21 14:55 ESTNewsSellas' galinpepimut-S combo shows promising action in early-stage solid tumor studiesN/A
2020-12-17 23:52 ESTNewsSellas Life Sciences strengthens balance sheet with addition of $30.5MN/A
2020-12-14 07:39 ESTNewsSellas Life Sciences prices $16.2M direct offeringN/A
2020-12-11 11:44 ESTNewsNelipepimut-S data from breast cancer study fails to lift SELLAS Life SciencesN/A
2020-12-08 12:06 ESTNewsSELLAS and 3D Medicines in exclusive license agreement for development and commercialization of GPS and GPS+ in Greater ChinaN/A
2020-11-26 21:35 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 21:13 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 05:25 ESTEarnings EstimateAn EPS average of -$0.35 is estimated for the quarter ending on March 31, 2021.Buy
2020-11-14 11:21 ESTNewsSELLAS Life Sciences EPS misses by $0.26N/A
2020-11-08 00:54 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 17:09 ESTFinancialsCompany financials have been released.Neutral
2020-09-26 14:03 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 06:16 ESTFinancialsCompany financials have been released.Neutral
2020-09-10 05:25 ESTNewsSELLAS Life gets green signal to initiate late-stage blood cancer study with GPS in FranceN/A
2020-09-01 21:38 ESTFinancialsCompany financials have been released.Neutral
2020-08-20 13:43 ESTAnalyst RatingThe Analyst Target Price has decreased from $8.5 to $8.Neutral
2020-08-17 01:43 ESTFinancialsCompany financials have been released.Neutral

About SELLAS Life Sciences Group, Inc (SLS):

SELLAS Life Sciences Group, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and is in various development phases as a potential treatment for ovarian cancer. It also develops nelipepimut-S that is in Phase 2b clinical trials for the treatment of breast cancer. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. SELLAS Life Sciences Group, Inc. was founded in 2012 and is headquartered in New York, New York.

SLS Quotes by TradingView

See Advanced Chart

General

  • Name SELLAS Life Sciences Group, Inc
  • Symbol SLS
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 5
  • Last Split Factor1:50
  • Last Split Date2019-11-08
  • Fiscal Year EndDecember
  • IPO Date2017-12-29
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Web URLhttp://www.sellaslifesciences.com
View More

Valuation

  • Trailing PE 0.62
  • Price/Book (Most Recent Quarter) 17.57
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.30
  • Return on Assets -55%
  • Return on Equity -220%
  • Earnings Per Share -$1.35
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 149.61 million
  • PE Ratio -1.86
  • Analyst Target Price $10
  • Book Value Per Share $0.84
View More

Share Statistics

  • Shares Outstanding 14.19 million
  • Shares Float 9.22 million
  • % Held by Insiders 198%
  • % Held by Institutions 14.24%
  • Shares Short 805001
  • Shares Short Prior Month 960419
  • Short Ratio 0.22
  • Short % of Float 6%
  • Short % of Shares Outstanding 6%
View More

Technicals

  • Beta 1.87
  • 52 Week High $12.18
  • 52 Week Low $1.46
  • 50 Day Moving Average 8.9
  • 200 Day Moving Average 5.21
View More

Dividends

  • Dividend Date 2019-11-08
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

SELLAS Life Sciences Group, Inc (SLS) Dividend Calendar:

SLS's last dividend payment was made to shareholders on November 8, 2019.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

SELLAS Life Sciences Group, Inc (SLS) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-13$N/A-$0.53-$0.27-96.3%
2020-06-302020-08-13$N/A-$0.66-$0.64-3.13%
2020-03-312020-05-14$N/A-$0.66
2019-12-312020-03-13$N/A-$1.54-$0.72-113.89%
2019-09-302019-11-14$N/A-$2.68-$1.00-168%
2019-06-302019-08-14$N/A-$6.50-$9.0027.78%
2019-03-312019-05-15$N/A-$11.00-$11.504.35%
2018-12-312019-03-22$N/A-$20.00-$11.75-70.21%
2018-09-302018-11-14$N/A-$26.50-$20.25-30.86%
2018-06-302018-08-14$N/A-$63.00-$51.50-22.33%
2018-03-312018-05-15$N/A-$83.50-$46.50-79.57%
2017-09-302017-11-09$N/A-$135.00-$4.50-2900%
2017-06-302017-08-14$N/A-$6.60-$5.40-22.22%
2017-03-312017-05-10$N/A-$13.50-$6.60-104.55%
2016-12-312017-03-15$N/A-$14.70-$15.605.77%
2016-09-302016-11-09$N/A-$18.00-$27.0033.33%
2016-06-302016-08-09$N/A$18.00-$37.50148%
2016-03-312016-05-10$N/A-$54.00-$38.40-40.63%
2015-12-312016-03-10$6.13 million-$72.00-$32.00-125%
2015-09-302015-11-09$-9514000-$2.20-$1.37-60.58%
2015-06-302015-08-06$3.38 million-$2.00-$1.84-8.7%
2015-03-312015-05-07$2.75 million-$1.60-$1.737.51%
2014-12-312015-03-05$9.48 million-$1.20-$2.1042.86%
2014-09-302014-11-03$-2884000-$0.05-$0.1154.55%
2014-06-302014-08-11$4.5 million-$5,100.00-$2,700.00-88.89%
2014-03-312014-05-06$-165000-$600.00-$2,062.5070.91%
2013-12-312014-03-17$1.32 million-$13,800.00-$2,766.67-398.79%
2013-09-302013-11-06$1.17 million-$3,300.00-$3,300.000%
2013-06-302013-08-08$N/A-$3,300.00-$3,112.50-6.02%
2013-03-312013-05-09$N/A-$3,300.00-$2,228.57-48.08%
2012-12-312013-03-12$N/A-$1,200.00-$3,042.8660.56%
2012-09-302012-11-13$N/A-$2,700.00-$2,550.00-5.88%
2012-06-302012-08-14$N/A-$210.00-$4,800.0095.63%
2012-03-312012-05-14$N/A-$15,600.00-$3,000.00-420%
2011-12-312012-03-28$1,200.00-$4,500.00126.67%
2011-09-302011-11-14$N/A-$3,900.00-$4,800.0018.75%
2011-06-302011-08-15$N/A-$1,200.00-$2,100.0042.86%
2011-03-312011-05-15-$5,672.40
2010-09-302010-11-15-$6,900.00-$7,050.002.13%
2010-06-302010-08-11-$3,600.00-$7,200.0050%
2010-03-312010-05-17-$7,200.00-$8,100.0011.11%
2009-12-312010-03-31-$11,400.00-$7,500.00-52%
2009-09-302009-11-16-$5,846.95
2009-06-302009-08-14-$11,100.00-$9,000.00-23.33%
2009-03-312009-05-15-$9,000.00-$8,700.00-3.45%
2008-12-312009-03-18-$8,700.00$2,400.00-462.5%
2008-09-302008-11-14-$7,500.00-$9,600.0021.88%
2008-06-302008-08-14-$10,200.00-$6,600.00-54.55%
2008-03-312008-04-15-$11,700.00-$6,000.00-95%

SELLAS Life Sciences Group, Inc (SLS) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Research Development N/A N/A 1.86 million 2.25 million 1.8 million
Income Before Tax N/A N/A -4.14 million -7.5 million -4.2 million
Selling General Administrative N/A N/A 2.2 million 2.4 million 2.39 million
Gross Profit N/A N/A N/A N/A N/A
Ebit N/A N/A -4.06 million -4.65 million -4.18 million
Operating Income N/A N/A -4.06 million -4.65 million -4.18 million
Income Tax Expense N/A N/A N/A -81000 N/A
Total Revenue N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A -103000 -2.85 million -18000
Net Income From Continuing Operations N/A N/A -4.14 million -7.42 million -4.2 million
Net Income Applicable to Common Shares -4.47 million -4.43 million N/A -7.42 million -11.47 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A N/A N/A N/A
Change to Liabilities -647000 -173000 N/A 239000 36000
Total Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Net Borrowings N/A N/A N/A N/A N/A
Total Cash Flow from Financial Activities N/A N/A 6.3 million 2.32 million 189000
Change to Operating Activities 1.29 million 888000 N/A 71000 158000
Change in Cash N/A N/A -531000 -1.86 million -3.63 million
Total Cash from Operating Activities -3.63 million -3.38 million -6.83 million -4.18 million -3.82 million
Depreciation N/A N/A N/A -200000 N/A
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities N/A N/A N/A N/A N/A
Change to Net Income 303000 429000 N/A 3.13 million 188000
Capital Expenditures N/A N/A N/A N/A N/A
Balance Sheet:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Total Liabailities N/A N/A 8.96 million 10.52 million 10.85 million
Total Stockholder Equity N/A N/A 8.06 million 6.09 million 10.64 million
Other Current Liabilities N/A N/A N/A N/A N/A
Total Assets N/A N/A 17.03 million 16.61 million 21.48 million
Common Stock 10000 7000 N/A 5000 5000
Other Current Assets 100000 N/A 84000 408000 115000
Retained Earnings -114.19 million -109.72 million -105.29 million -101.15 million -93.73 million
Other Liabilities 5.47 million 5.49 million N/A 5.23 million 5.27 million
Other Assets 651000 687000 N/A 536000 553000
Cash N/A N/A 6.75 million 7.28 million 9.12 million
Total Current Liabilities 4.22 million N/A 3.64 million 5.29 million 5.57 million
Other Stockholder Equity N/A N/A N/A N/A N/A
Property, Plant & Equipment 911000 984000 N/A 217000 306000
Total Current Assets 9.33 million N/A 8.79 million 8.24 million 10.21 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 334000 -3.83 million N/A -1.52 million 223000
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 1.78 million N/A 2.62 million 3.9 million 3.76 million

SELLAS Life Sciences Group, Inc (SLS) Chart:

SELLAS Life Sciences Group, Inc (SLS) News:

Below you will find a list of latest news for SELLAS Life Sciences Group, Inc (SLS) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

SELLAS Life Sciences Group, Inc (SLS) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-05-170.51.35CALL0 19746.98TRUE00
2024-05-1710.2CALL10 443133.02TRUE-0.1-0.33
2024-05-171.50.07CALL55 5485129.9FALSE-0.03-0.3
2024-05-1720.05CALL0 80750FALSE00
2024-05-1730.05CALL0 45970FALSE00
2024-05-1740.09CALL0 2030FALSE00
2024-05-1750.1CALL0 1170FALSE00
2024-05-170.50.05PUT0 130FALSE00
2024-05-1710.05PUT0 14580FALSE00
2024-05-171.50.4PUT0 3630TRUE00
2024-05-1720.55PUT0 233281.09TRUE00
2024-05-1731.6PUT0 3698.06TRUE00
2024-05-1740PUT0 0450.85TRUE00
2024-05-1750PUT0 0506.44TRUE00
2024-06-210.50.55CALL5 5237.57TRUE0.550
2024-06-2110.4CALL27 87111.27TRUE0.40
2024-06-211.50.2CALL0 11250FALSE00
2024-06-2120.1CALL8 4282140.5FALSE00
2024-06-2130.05CALL0 3950FALSE00
2024-06-2140.05CALL0 150FALSE00
2024-06-2150.06CALL0 60FALSE00
2024-06-210.50.05PUT0 1050FALSE00
2024-06-2110.12PUT0 1930FALSE00
2024-06-211.50.33PUT0 100TRUE00
2024-06-2120PUT0 0191.8TRUE00
2024-06-2130PUT0 0303.47TRUE00
2024-06-2140PUT0 0261.26TRUE00
2024-06-2150PUT0 0229.91TRUE00
2024-07-190.51CALL0 20186.49TRUE00
2024-07-1910.4CALL0 12117131.16TRUE00
2024-07-191.50.25CALL0 8899127.13FALSE00
2024-07-1920.15CALL0 14278122.64FALSE00
2024-07-1930.1CALL0 319148.4FALSE00
2024-07-1940.1CALL82 1442193.99FALSE0.020.25
2024-07-1950.1CALL0 5050FALSE00
2024-07-1960.1CALL0 3700FALSE00
2024-07-190.50PUT0 00FALSE00
2024-07-1910.15PUT2 22140.09FALSE0.150
2024-07-191.50PUT0 00TRUE00
2024-07-1921.05PUT0 3660TRUE00
2024-07-1930PUT0 0265.35TRUE00
2024-07-1940PUT0 0291.98TRUE00
2024-07-1950PUT0 0381.7TRUE00
2024-07-1960PUT0 0272.33TRUE00
2024-08-160.50CALL0 0445.93TRUE00
2024-08-1610.5CALL0 10330.03TRUE00
2024-08-161.50.25CALL0 140125.84FALSE00
2024-08-1620.15CALL9 2404113.84FALSE0.150
2024-08-1630.15CALL1 17159.65FALSE0.150
2024-08-1640.1CALL0 3100FALSE00
2024-08-1650.1CALL0 2010FALSE00
2024-08-160.50PUT0 00FALSE00
2024-08-1610.32PUT0 210FALSE00
2024-08-161.50PUT0 0190.57TRUE00
2024-08-1621.05PUT0 72124.75TRUE00
2024-08-1630PUT0 0130.97TRUE00
2024-08-1640PUT0 0234.84TRUE00
2024-08-1650PUT0 0219.24TRUE00
2024-09-200.51.1CALL0 9385.09TRUE00
2024-09-2010.35CALL0 48105.28TRUE00
2024-09-201.50.35CALL0 151992.66FALSE00
2024-09-2020.15CALL0 2228121.48FALSE00
2024-09-2030.18CALL0 20FALSE00
2024-09-2040.1CALL1 10142.72FALSE0.10
2024-09-2050.1CALL0 300FALSE00
2024-09-200.50PUT0 0173.42FALSE00
2024-09-2010.4PUT0 10FALSE00
2024-09-201.50.56PUT0 10TRUE00
2024-09-2021.05PUT0 2148.52TRUE00
2024-09-2031.7PUT0 30162.03TRUE00
2024-09-2040PUT0 0163.99TRUE00
2024-09-2050PUT0 0211.61TRUE00
2024-10-180.51CALL0 862204.09TRUE00
2024-10-1810.5CALL2 141895.17TRUE-0.05-0.09
2024-10-181.50.35CALL21 18783112.35FALSE00
2024-10-1820.3CALL135 16026131.36FALSE0.10.5
2024-10-1830.16CALL0 161183.16FALSE00
2024-10-1840.2CALL0 2050FALSE00
2024-10-1850.7CALL30 326324.5FALSE0.70
2024-10-180.50.07PUT0 200FALSE00
2024-10-1810PUT0 100FALSE00
2024-10-181.50PUT0 0130.4TRUE00
2024-10-1821PUT0 4122.81TRUE00
2024-10-1832PUT0 10142.3TRUE00
2024-10-1840PUT0 0152.22TRUE00
2024-10-1850PUT0 0239.66TRUE00

Latest SLS Trades:

Date Shares Price
Jun 13, 2022 7:06 PM EST5$2.29
Jun 13, 2022 7:12 PM EST100$2.265
Jun 13, 2022 7:30 PM EST100$2.265
Jun 13, 2022 7:39 PM EST2$2.28
Jun 13, 2022 7:40 PM EST100$2.27

SELLAS Life Sciences Group, Inc (SLS) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-11EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1390478/999999999520001404/9999999995-20-001404-index.htm
2018-07-26UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1390478/000000000018022947/0000000000-18-022947-index.htm
2019-05-29UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1390478/000000000019009082/0000000000-19-009082-index.htm
2019-10-01UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1390478/000000000019014150/0000000000-19-014150-index.htm
2020-06-05UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1390478/000000000020005052/0000000000-20-005052-index.htm
2020-08-21UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1390478/000000000020007844/0000000000-20-007844-index.htm
2018-09-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1390478/000089924318025346/0000899243-18-025346-index.htm
2019-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1390478/000089924319008194/0000899243-19-008194-index.htm
2019-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1390478/000089924319008198/0000899243-19-008198-index.htm
2019-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1390478/000089924319008199/0000899243-19-008199-index.htm
2019-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1390478/000089924319008201/0000899243-19-008201-index.htm
2019-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1390478/000089924319008202/0000899243-19-008202-index.htm
2019-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1390478/000089924319008204/0000899243-19-008204-index.htm
2019-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1390478/000089924319008205/0000899243-19-008205-index.htm
2019-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1390478/000089924319008206/0000899243-19-008206-index.htm
2019-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1390478/000089924319008207/0000899243-19-008207-index.htm
2018-07-18SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1390478/000090266418002884/0000902664-18-002884-index.htm
2019-01-17SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1390478/000090266419000274/0000902664-19-000274-index.htm
2018-07-23SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1390478/000101359418000463/0001013594-18-000463-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1390478/000101359420000125/0001013594-20-000125-index.htm
2019-02-12SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1390478/000103738919000077/0001037389-19-000077-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1390478/000103738920000128/0001037389-20-000128-index.htm
2019-10-30424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1390478/000110465919057371/0001104659-19-057371-index.htm
2019-10-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000110465919057956/0001104659-19-057956-index.htm
2019-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000110465919060564/0001104659-19-060564-index.htm
2020-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000110465920002021/0001104659-20-002021-index.htm
2020-01-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000110465920002807/0001104659-20-002807-index.htm
2020-01-10424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1390478/000110465920002811/0001104659-20-002811-index.htm
2020-01-17SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1390478/000110465920004932/0001104659-20-004932-index.htm
2020-03-13S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1390478/000110465920033156/0001104659-20-033156-index.htm
2020-03-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1390478/000110465920034284/0001104659-20-034284-index.htm
2020-03-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1390478/000110465920034285/0001104659-20-034285-index.htm
2020-03-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1390478/000110465920034286/0001104659-20-034286-index.htm
2020-03-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1390478/000110465920034288/0001104659-20-034288-index.htm
2020-03-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1390478/000110465920034289/0001104659-20-034289-index.htm
2020-03-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1390478/000110465920034290/0001104659-20-034290-index.htm
2020-03-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1390478/000110465920034291/0001104659-20-034291-index.htm
2020-04-23DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1390478/000110465920049860/0001104659-20-049860-index.htm
2020-04-24DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1390478/000110465920050563/0001104659-20-050563-index.htm
2020-05-29S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1390478/000110465920067795/0001104659-20-067795-index.htm
2020-06-03DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1390478/000110465920069457/0001104659-20-069457-index.htm
2020-06-09CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1390478/000110465920071368/0001104659-20-071368-index.htm
2020-06-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000110465920072436/0001104659-20-072436-index.htm
2020-06-11424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1390478/000110465920072467/0001104659-20-072467-index.htm
2020-08-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000110465920089747/0001104659-20-089747-index.htm
2020-08-14S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1390478/000110465920095588/0001104659-20-095588-index.htm
2020-08-21CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1390478/000110465920097531/0001104659-20-097531-index.htm
2019-04-05S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1390478/000114420419018433/0001144204-19-018433-index.htm
2019-05-23S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1390478/000114420419028003/0001144204-19-028003-index.htm
2019-05-24DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1390478/000114420419028175/0001144204-19-028175-index.htm
2019-05-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000114420419029019/0001144204-19-029019-index.htm
2019-05-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000114420419029269/0001144204-19-029269-index.htm
2019-06-06S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1390478/000114420419030128/0001144204-19-030128-index.htm
2019-06-13S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1390478/000114420419030762/0001144204-19-030762-index.htm
2019-06-13CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1390478/000114420419030766/0001144204-19-030766-index.htm
2019-06-13CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1390478/000114420419030768/0001144204-19-030768-index.htm
2019-06-18424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1390478/000114420419031239/0001144204-19-031239-index.htm
2019-06-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000114420419031351/0001144204-19-031351-index.htm
2019-07-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000114420419033573/0001144204-19-033573-index.htm
2019-07-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000114420419034049/0001144204-19-034049-index.htm
2019-07-26PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1390478/000114420419036263/0001144204-19-036263-index.htm
2019-08-05DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1390478/000114420419037528/0001144204-19-037528-index.htm
2019-09-20S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1390478/000114420419045463/0001144204-19-045463-index.htm
2019-10-04S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1390478/000114420419047400/0001144204-19-047400-index.htm
2019-10-04CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1390478/000114420419047401/0001144204-19-047401-index.htm
2018-07-13424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1390478/000119312518217974/0001193125-18-217974-index.htm
2018-07-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000119312518220669/0001193125-18-220669-index.htm
2018-07-19S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1390478/000119312518221592/0001193125-18-221592-index.htm
2018-07-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000119312518223727/0001193125-18-223727-index.htm
2018-07-23SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1390478/000119312518223824/0001193125-18-223824-index.htm
2018-07-25CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1390478/000119312518225863/0001193125-18-225863-index.htm
2018-07-26424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1390478/000119312518227864/0001193125-18-227864-index.htm
2018-07-26424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1390478/000119312518227881/0001193125-18-227881-index.htm
2018-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000119312518239831/0001193125-18-239831-index.htm
2018-10-10SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1390478/000119312518296150/0001193125-18-296150-index.htm
2018-10-178-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000119312518301115/0001193125-18-301115-index.htm
2019-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000119312519003893/0001193125-19-003893-index.htm
2019-06-24SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1390478/000119312519180113/0001193125-19-180113-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1390478/000119312520038502/0001193125-20-038502-index.htm
2018-12-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1390478/000120919118063530/0001209191-18-063530-index.htm
2019-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1390478/000120919119001612/0001209191-19-001612-index.htm
2019-10-09CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1390478/000130049119000007/0001300491-19-000007-index.htm
2018-07-23SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1390478/000138713118003284/0001387131-18-003284-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1390478/000138713119001111/0001387131-19-001111-index.htm
2019-06-24SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1390478/000138713119004559/0001387131-19-004559-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1390478/000138713120001689/0001387131-20-001689-index.htm
2020-08-25SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1390478/000138713120007841/0001387131-20-007841-index.htm
2018-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1390478/000139047818000022/0001390478-18-000022-index.htm
2018-10-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047818000025/0001390478-18-000025-index.htm
2018-10-058-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047818000027/0001390478-18-000027-index.htm
2018-10-248-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047818000030/0001390478-18-000030-index.htm
2018-11-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047818000032/0001390478-18-000032-index.htm
2018-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1390478/000139047818000035/0001390478-18-000035-index.htm
2018-11-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047818000037/0001390478-18-000037-index.htm
2018-12-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047818000039/0001390478-18-000039-index.htm
2018-12-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047818000043/0001390478-18-000043-index.htm
2019-02-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047819000007/0001390478-19-000007-index.htm
2019-03-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047819000011/0001390478-19-000011-index.htm
2019-03-2210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1390478/000139047819000017/0001390478-19-000017-index.htm
2019-03-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047819000019/0001390478-19-000019-index.htm
2019-04-3010-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1390478/000139047819000023/0001390478-19-000023-index.htm
2019-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047819000028/0001390478-19-000028-index.htm
2019-05-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1390478/000139047819000030/0001390478-19-000030-index.htm
2019-07-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047819000033/0001390478-19-000033-index.htm
2019-07-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047819000035/0001390478-19-000035-index.htm
2019-07-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047819000037/0001390478-19-000037-index.htm
2019-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047819000044/0001390478-19-000044-index.htm
2019-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1390478/000139047819000045/0001390478-19-000045-index.htm
2019-09-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047819000048/0001390478-19-000048-index.htm
2019-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1390478/000139047819000056/0001390478-19-000056-index.htm
2019-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047819000057/0001390478-19-000057-index.htm
2019-11-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047819000061/0001390478-19-000061-index.htm
2020-03-1310-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1390478/000139047820000007/0001390478-20-000007-index.htm
2020-03-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047820000009/0001390478-20-000009-index.htm
2020-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1390478/000139047820000014/0001390478-20-000014-index.htm
2020-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047820000015/0001390478-20-000015-index.htm
2020-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1390478/000139047820000026/0001390478-20-000026-index.htm
2020-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1390478/000139047820000029/0001390478-20-000029-index.htm
2020-08-31DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1390478/000139047820000030/0001390478-20-000030-index.htm
2020-09-21SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1390478/000149315220018054/0001493152-20-018054-index.htm
2019-01-03SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1390478/000153561019000006/0001535610-19-000006-index.htm
2018-07-26EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1390478/999999999518001908/9999999995-18-001908-index.htm
2019-06-13EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1390478/999999999519001347/9999999995-19-001347-index.htm
2019-10-11EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1390478/999999999519002300/9999999995-19-002300-index.htm
2020-06-11EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1390478/999999999520001404/9999999995-20-001404-index.htm
2020-08-24EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1390478/999999999520002237/9999999995-20-002237-index.htm

SELLAS Life Sciences Group, Inc (SLS) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of SELLAS Life Sciences Group, Inc (SLS). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 198%
Institutional Ownership: 1424%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-03-12John Thomas BurnsVP, Finance & Corp ControllerBuy15,000.0015,000.00https://www.sec.gov/Archives/edgar/data/1390478/000110465920034284/0001104659-20-034284-index.htm
2020-03-12BARBARA A WOODEVP, Gen. Counsel, Corp. Sec.Buy35,000.0035,000.00https://www.sec.gov/Archives/edgar/data/1390478/000110465920034291/0001104659-20-034291-index.htm
2018-12-31Angelos M. StergiouPresident and CEOSell23,277.001.2529,189.36426,858.00https://www.sec.gov/Archives/edgar/data/1390478/000120919119001612/0001209191-19-001612-index.htm
2020-03-12Angelos M. StergiouPresident and CEOBuy95,000.0095,000.00https://www.sec.gov/Archives/edgar/data/1390478/000110465920034286/0001104659-20-034286-index.htm